266 results about "Osteoporosis" patented technology

The present application relates to animal bifidobacterium lactis Ca360 and its application. The present application also provides the application of animal bifidobacterium lactis in promoting the absorption and transport of minerals, improving osteoporosis, iron deficiency anemia and zinc deficiency. The animal bifidobacterium lactis of the present application can promote the absorption and transport of minerals, improve osteoporosis, iron deficiency anemia and zinc deficiency.

The invention relates to bifidobacterium animalis subsp. Lactis Ca360 and application thereof. The invention further provides application of the animal bifidobacterium subsp. Lactis in promoting absorption and transport of mineral substances and improving osteoporosis, iron-deficiency anemia and zinc deficiency. The bifidobacterium animalis subsp. Lactis disclosed by the invention can promote absorption and transport of mineral substances and improve osteoporosis, iron-deficiency anemia and zinc deficiency.

The invention provides a novel anti-human DKK-1 monoclonal antibody, aiming at solving the problems that osteoporosis antibody drugs developed in China at present are biosimilar drugs, and the existing antibody drugs also have certain defects, for example, Romosozumab is easy to cause cardiovascular adverse reactions, and DKK-1 antibody drugs aiming at osteoporosis do not appear on the market globally. According to the present invention, the rarely researched DKK-1 is adopted as the target spot to research the humanized DKK-1 antibody, such that the foundation is laid for the clinic and the effectiveness of the DKK-1 antibody, the treatment approach with the excellent effect is provided for the patient, and the problem of the lack of the innovation of the domestic antibody drug for treating osteoporosis can be hopefully solved.

The invention provides a traditional Chinese medicine composition for treating osteoporosis. The traditional Chinese medicine composition comprises rhizoma drynariae, eucommia ulmoides, fructus psoraleae, ligusticum wallichii, raw radix astragali, codonopsis pilosula, radix cyathulae and radix achyranthis bidentatae. The traditional Chinese medicine composition can be used for effectively treating osteoporosis, myopenia-osteoporosis and climacteric osteoporosis.

The invention belongs to the technical field of microbial function development, and particularly relates to lactobacillus plantarum YD666 and application of the lactobacillus plantarum YD666 in products for slowing down muscle atrophy and osteoporosis, the lactobacillus plantarum YD666 is preserved in the China Center for Type Culture Collection with the preservation number of CCTCC No: M 2025897, a preparation method of a lactobacillus plantarum YD666 bacterial suspension is provided, and the lactobacillus plantarum YD666 bacterial suspension can be used for preparing the lactobacillus plantarum YD666 bacterial suspension with the preservation number of CCTCC No: M 2025897. According to the lactobacillus plantarum YD666 and the application of the lactobacillus plantarum YD666 bacterial suspension in preparation of products for slowing down muscle atrophy and osteoporosis, the weight index of skeletal muscles of suspended tail rats can be increased by slowing down muscle weight loss caused by weightlessness; growth of muscle fibers is promoted, and the proportion of conversion from slow muscles to fast muscles is reduced, so that a weightlessness environment is resisted; the muscle movement contraction strength of the suspended tail rats is maintained, so that the application of relieving muscle atrophy under weightlessness is achieved, and the device is suitable for astronauts, crowds lack of movement and bedridden people who suffer from long-term illness and has wide market potential and application prospects.

The invention belongs to the technical field of food and medicine, and relates to application of corn germ concentrated powder in improvement of osteoarthritis. The invention particularly relates to application of corn germ concentrated powder, namely corn antioxidant multienzyme, in preparation of medicines or health-care foods for treating rheumatoid arthritis and osteoporosis. In the corn germ concentrated powder, superoxide dismutase / (U / g) is greater than or equal to 8500, glutathione peroxidase / (U / g) is greater than or equal to 5000, and catalase / (U / g) is greater than or equal to 750. The corn germ concentrated powder can also be prepared by the following method: cleaning corn, germinating, adding water into the germinated corn, grinding and pulping, adding a settling agent into the corn steep liquor, standing, taking supernate, adding part of sodium ascorbate, performing temperature-controlled concentration, adding the rest sodium ascorbate and a stabilizer into the concentrated solution, and uniformly mixing to obtain the corn germ concentrated powder. And drying at controlled temperature, crushing, and mixing with a proper amount of silicon dioxide. The prepared corn germ concentrated powder has the effect of resisting rheumatoid arthritis.

A traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 7-13 parts of Acori Tatarinowii Rhizoma, 14-22 parts of Curcuma phaeocaulis, 14-22 parts of Cuscuta chinensis, 11-19 parts of oyster, 18-30 parts of Verbena officinalis, 12-19 parts of Schisandra chinensis, 14-22 parts of Poria cocos, 24-37 parts of Rhizoma Dioscoreae Hypoglaucae, 4-8 parts of licorice, and 4-9 parts of Indigo naturalis. The traditional Chinese medicine composition tonifies the kidney to consolidate the essence, and treats osteoporosis and prostatitis.

The invention relates to a beta-CTx binding antibody or an antigen binding fragment thereof, the beta-CTx binding antibody comprises a heavy chain variable region and a light chain variable region, and the heavy chain variable region and the light chain variable region contain HCDR and LCDR sequences; the invention also relates to corresponding isolated nucleic acid molecules, expression vectors and host cells. In addition, the invention also relates to a kit and a method for diagnosing osteoporosis in a subject.

The invention relates to the technical field of biomedical materials, in particular to a preparation process of novel composite bone cement with biological activity, which comprises the following steps: calcining calcium phosphate in a calcining furnace at 800-1000 DEG C for 3 hours, cooling to 20 DEG C, grinding the calcium phosphate by using a grinding machine until the diameter is less than 100 mu m, and drying to obtain the novel composite bone cement with biological activity. Calcium phosphate micro powder is obtained; by fusing the calcium phosphate, the nano-hydroxyapatite, the bioglass and the collagen, the material has a mechanical support function of an inorganic phase and biological activity of an organic phase, the nano-hydroxyapatite is extremely similar to human bone minerals and can promote osteoblast attachment and growth, and the collagen constructs a bionic microenvironment and accelerates new bone formation, so that the material can be used for treating osteoporosis. The bone repair efficiency is obviously improved.

The invention discloses a preparation method and application of nano-enzyme molecularly imprinted detection particles, a molecularly imprinted material is developed on the basis of a FeN3P nano-enzyme material, the molecularly imprinted material is fixed on filter paper to realize high-sensitivity and high-selectivity detection of 25-(OH) D3, real-time field detection of the molecularly imprinted material is realized by matching with a self-researched mobile phone APP: Visual Method, and the nano-enzyme molecularly imprinted detection particles have very high practical application value. Accurate data support is provided for early warning and personalized intervention of osteoporosis, community screening and long-term health management lack of 25 (OH) D3 can be promoted, and the method has important scientific value and social significance in reduction of the incidence rate of osteoporosis and optimization of medical resource allocation.

The invention belongs to the field of medicine, and discloses application of POCM-NP-coated A939572 in preparation of a medicine for treating osteoporosis, the POCM-NP-coated A939572 comprises osteoclast precursor cell membrane vesicles and NP-coated A939572 loaded on the osteoclast precursor cell membrane vesicles, and the NP-coated A939572 is PLGA (poly (lactic-co-glycolic acid)) nanoparticles entrapped with the NP-coated A939572. The POCM-NP-coated A939572 obtained by loading the nanoparticles loaded with the A939572 small molecule medicine into the osteoclast precursor cell membrane vesicles has the effect of relieving the osteoporosis, can inhibit osteoclast differentiation and can be used for preventing, treating and relieving the osteoporosis.

The invention provides a polyketone compound and application thereof in preparation of an osteoclast differentiation inhibitor, and relates to the technical field of marine natural products. The compound is obtained by separation and purification from a fermentation culture of a marine fungus talaromyces sp. GMIMD 02524 (the preservation number is GDMCC No. 66968), the compound is named as talaromyces furanone A, and the structure of the compound is as shown in the formula (I) in the specification. The compound can effectively inhibit RANKL-induced osteoclast differentiation by inhibiting an NF-kappa B signal channel in vitro, and has no obvious cytotoxicity at an effective concentration. Therefore, the compound talaromyfuranone A can be used for developing medicines for preventing and treating osteoclast-related osteolytic diseases such as osteoporosis and the like, and has a good application prospect.

The invention provides application of polypeptide or related biological materials thereof in inhibition of osteoclast differentiation. The polypeptide with the amino acid sequence as shown in SEQ ID NO: 1 or related biological materials thereof can remarkably inhibit osteoclast differentiation, further effectively treat and / or prevent osteoporosis and is suitable for preparing products for treating and / or preventing osteoporosis.

The invention discloses a preparation method and application of a multifunctional layered nanosheet. The biomimetic hydrogel is prepared through a hydrothermal method, folic acid (FA) is modified on the surface of the biomimetic hydrogel, and the biomimetic hydrogel has the capacity of targeted recognition of pro-inflammatory phenotype macrophages, has the biomimetic activity of multiple enzymes such as superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) and can effectively remove ROS; meanwhile, a succinate dehydrogenase (SDH) inhibitor dimethylmalonic acid (DMM) is loaded in an intercalation mode of the nano material, SDH activity is inhibited in a slow release mode, ROS outbreak caused by mitochondrial reverse electron transfer (RET) is blocked from the source, then a mitochondrial autophagy pathway mediated by BNIP3-LC3B is started, and dynamic and steady state recovery of mitochondria is achieved. The system finally realizes macrophage mitochondrial function reconstruction, oxidation environment improvement and transfer of healthy mitochondria to osteoblasts, so that the osteogenic differentiation capability is recovered, and the effect of treating osteoporosis is achieved.

The invention discloses a long-chain non-coding RNA (Ribonucleic Acid) and application thereof in regulating osteogenic differentiation of bone marrow mesenchymal stem cells. It is found that overexpression of long-chain non-coding RNA (lncRNA Gm20628) with the nucleotide sequence shown in SEQ ID NO.1 in bone marrow mesenchymal stem cells can effectively promote osteogenic differentiation of the bone marrow mesenchymal stem cells, and then bone defect repair of a mouse with skull injury is promoted. Therefore, the invention provides application of the expression promoter of the lncRNA Gm20628 in preparation for enhancing bone regeneration, repairing bone defects and treating osteoporosis and bone formation disorder related diseases. The method is not only beneficial to treatment of diseases related to the bone marrow mesenchymal stem cells, but also beneficial to construction of bone organs.

The invention discloses application of a compound with a benzo-aza structure in preparation of a medicine for inhibiting osteoclast formation, the structure of the compound is shown as a formula (1), and R substituent is one of H, OCH3, Br, F and i-Pr. Cell experiments prove that the compound with the benzo-aza structure has a remarkable inhibiting effect on RANKL-induced osteoclast differentiation and marker gene expression, can be used as a candidate medicine which is novel in structure and is used for inhibiting osteoclast formation, and is used for targeting osteoclast to treat osteoporosis related diseases.

The present disclosure relates to compounds of Formula (I′):and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating orexin-2 receptor activity and may be used in the treatment of disorders in which orexin-2 receptor activity is implicated, such as narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or facilitating emergence from anaesthesia.

The invention discloses an application of an AMPK (adenosine monophosphate kinase) activator or a PPAR (peroxisome proliferator activated receptor) gamma inhibitor in preparation of a medicine for preventing or treating diabetic osteoporosis. The invention discloses a key effect of a brand new signal channel, namely an AMPK-PPAR gamma-ERS axis, in osteogenic differentiation disorder of diabetes mellitus, and provides a method for preventing and treating diabetic osteoporosis by regulating and controlling the signal axis by taking metformin as a core. The invention provides new guidance for research and development of medicines for treating osteoporosis, and has potential clinical application and mechanism research values.

The invention relates to the technical field of gene therapy and drug development, and provides application of a UCH37 inhibitor in preparation of a drug for treating osteoporosis. The expression level of UCH37 in blood of osteoporosis patients is obviously higher than that of UCH37 in blood of healthy people, and the UCH37 is in positive correlation with osteoclast active markers such as NFATC1 and MMP9. The UCH37 inhibitor is applied to preparation of the medicine for treating osteoporosis and directly targets UCH37, the curative effect does not depend on the expression change of ADRM1, no matter the ADRM1 of osteoporosis patients is in a low or high expression state, an osteoclast activation pathway can be stably blocked, the consistency of treatment effects of different individuals is ensured, the range of applicable people of the medicine is expanded, and the application prospect is broad. The compound has the characteristics of clear action mechanism and wide application range, and provides important theoretical basis and conversion prospect for developing novel and efficient medicines for treating osteoporosis.

Provided is a use of dipsaci radix-derived extracellular vesicle-like nanoparticles (DREVNs) in preparation of a drug for preventing or treating orthopedic diseases. In this application, EVs are creatively extracted from dipsaci radix and purified, and the physiological efficacy of the EVs is studied. It has been found that the EVs can be fully internalized by bone marrow mesenchymal stem cells (BMSCs), can promote the osteogenic differentiation of BMSCs by activating a BMP2 / Smads signaling pathway, promote the calcified nodule formation in BMSCs, and promote the expression of osteogenic differentiation-associated genes ALP, OCN, RUNX2, and COL1, and have bone targetability in vivo. The EVs can be intragastrically administered to alleviate the osteoporosis (OP) in postmenopausal mice. Therefore, the EVs have the potential of being used to prepare drugs for preventing or treating orthopedic diseases, and provide a new strategy for the prevention or treatment of orthopedic diseases.

The invention discloses a milk-derived polypeptide for promoting osteoblast proliferation and differentiation and application thereof, and belongs to the technical field of bioactive peptides. The invention provides a milk-derived bioactive peptide WLKPDPS. The milk-derived bioactive peptide WLKPDPS has extremely high biological safety and a function of promoting osteoblast proliferation and differentiation. The milk-derived bioactive polypeptide WLKPDPS disclosed by the invention has an obvious effect of promoting osteoblast proliferation, can obviously promote osteoblast mineralization, and is expected to be used for preparing medicines for promoting osteoblast proliferation and preventing osteoporosis. The milk-derived bioactive polypeptide WLKPDPS is convenient to synthesize, can be industrially produced, and has a good application prospect in the fields of foods, medicines, cosmetics and the like.

The invention relates to a colla corii asini-concha haliotidis compound as well as a preparation method and application thereof, and belongs to the technical field of medicines and health-care products. The colla corii asini-concha haliotidis compound provided by the invention comprises the following components in parts by weight: a) 38-42 parts of colla corii asini; b) 15-25 parts of concha haliotidis; and c) 1-5 parts of an auxiliary material, wherein the auxiliary material is selected from one or more of polyvinylpyrrolidone, copovidone, hydroxy propyl cellulose and hydroxyethyl cellulose. The donkey-hide gelatin and concha haliotidis compound is prepared by using a hot melt extrusion technology, so that the smell, wettability, dispersity and other properties of the donkey-hide gelatin are obviously improved, and the donkey-hide gelatin compound shows a good effect in an osteoporosis rat model and a calcium-deficient mouse model. The preparation process is simple and controllable, and has a good market prospect.

The present application relates to the technical field of multi-cause intelligent analysis in medical diagnosis, and particularly relates to an osteoporosis detection method and system based on data analysis and artificial intelligence. The method comprises the following steps: S1: obtaining primary osteoporosis data and secondary osteoporosis data and determining synergistic data, and determining antagonistic masking data according to the synergistic data; S2: obtaining a first layer dominant right conversion sequence according to the synergistic data and the antagonistic masking data; S3: obtaining a synergistic data internal dominant relationship sequence and an antagonistic masking data internal dominant relationship sequence respectively according to the synergistic data and the antagonistic masking data, and generating a complete dominant relationship graph in combination with the first layer dominant right conversion sequence. The present application separates and analyzes the synergistic and antagonistic modes of primary and secondary osteoporosis, constructs a dynamic dominant right sequence, quantifies the evolution of mixed cause weights, and provides data support for individualized precise diagnosis and treatment.

The invention relates to the field of biological medicine, and discloses a pTH long-acting polypeptide compound as well as preparation and application thereof. According to the polypeptide, at least one amino acid residue of the 13th, 26th and 27th amino acid residues of a pTH (1-34) parent peptide sequence is connected with octadecanedioic acid or eicosanoic acid and a derivative modification group of octadecanedioic acid or eicosanoic acid, and the polypeptide is covalently combined with a polypeptide skeleton through an AEA-AEA-gamma-Glu connecting unit. The binding capacity of the polypeptide and serum albumin is remarkably enhanced by utilizing a fatty acid side chain modification means, and meanwhile, the half-life period is prolonged. The pTH long-acting polypeptide compound disclosed by the invention has remarkable osteogenic activity promoting effect, can promote proliferation of MC3T3-E1 cells and generate osteogenic markers and calcium nodules under osteogenic induction conditions, and the binding capacity of the pTH long-acting polypeptide compound and serum albumin is improved by 2-6 times. The invention further provides a solid-phase synthesis method of the polypeptide compound and a pharmaceutical composition containing the polypeptide compound, the polypeptide compound can be used for treating osteoporosis and parathyroid hypofunction, and the compliance problem that an existing medicine needs to be injected every day is effectively solved.

The invention relates to the field of in-vitro diagnostic reagents, in particular to application of a reagent for detecting TREM2 in preparation of a diagnostic kit for chronic kidney disease osteoporosis. The invention finds that the TREM2 signal channel is closely related to the common pathological background of chronic kidney disease and osteoporosis. Therefore, the TREM2 can be used as an expression characteristic and a molecular diagnosis marker in the chronic kidney disease-related osteoporosis, so that the chronic kidney disease-related osteoporosis can be subjected to early diagnosis. On the basis, the invention provides application of the TREM2 detection reagent in preparation of the chronic kidney disease osteoporosis diagnosis kit, and the application prospect is good.

The application discloses an osteoporosis risk grading prediction method based on clinical prior logic gating, acquires multi-modal clinical data of a patient to obtain a standardized feature vector group, constructs and trains an osteoporosis risk grading prediction neural network model, including a double-flow feature coding module, a logic gating fusion module and a cascaded classification prediction module, inputs the standardized feature vector group after splicing processing to the trained neural network model, and outputs an osteoporosis risk grading prediction result. The application converts the diagnosis logic in the clinical guideline into an attention gating mechanism in the neural network by designing a double-flow architecture, and combines a screening-grading cascaded strategy, so that the existing structured data (demography, test single, medical history) in the hospital information system can be directly used to realize low-cost, high-precision and clinically interpretable osteoporosis risk grading without additional image examination.

The invention belongs to the field of medicaments, and discloses a nano-medicinal preparation capable of treating diabetes and a preparation method of the nano-medicinal preparation. The preparation method comprises the following steps: carrying out hydrothermal reaction on fructose-1, 6-strontium diphosphate, vanadium pentoxide and ergothioneine to prepare strontium-vanadate organic framework nanoparticles; the strontium-vanadate organic framework nano-particles, dopamine and polylysine are blended, embedding of polydopamine is achieved under the alkaline condition, polylysine-polydopamine co-embedded organic framework nano-particles are formed, and the nano-drug preparation for treating diabetes is obtained. The nano medicinal preparation can release the vanadyl complex and the ergothioneine and improve the blood strontium concentration and the half-life period thereof, so that the blood sugar is controlled, the symptoms of diabetes mellitus are improved, and the symptoms of osteoporosis, arteriosclerosis and the like complicated by diabetes mellitus are improved.

The present invention belongs to the field of medicine and relates to the use of benzothiazinone vinylidene indene compounds in the preparation of osteoclast differentiation inhibitors. The present invention uses tartrate-resistant acid phosphatase (TRAP) staining and reverse transcription real-time fluorescence quantitative polymerase chain reaction (RT-qPCR) technology to confirm for the first time that this series of compounds can significantly inhibit RANKL-induced osteoclast differentiation and the formation of multinucleated osteoclasts, and are non-cytotoxic at concentrations of 5μM and below. Based on these findings, the benzothiazinone vinylidene indene compounds provided by the present invention can be used as candidate drug molecules for novel osteoclast differentiation inhibitors, for the prevention and / or treatment of bone metabolic diseases caused by excessive activation of osteoclasts, such as osteoporosis, periprosthetic bone dissolution, tumor metastasis bone destruction, and rheumatoid arthritis.

The invention relates to corn with the efficacy of preventing or improving osteoporosis symptoms. The mass ratio of campesterol to stigmasterol to beta-sitosterol in the corn is 1: (0.5-5): (1-5). The planted corn can significantly improve osteoporosis, and has the advantages of high yield of planted corn and corn straw, good taste, convenience in use, high bioavailability, safety, effectiveness, high comprehensive utilization rate of resources, greenness, environmental protection and the like.